AIMS: The vascular endothelial growth factor (VEGF) stimulates angiogenesis by induction of vessel permeability, proliferation, and migration of endothelial cells, an important process in ischaemic diseases. ADP-ribosylation factor (ARF) nucleotide-binding site opener (ARNO) (cytohesin-2) is a guanine exchange factor important for cellular signalling through ARF GTPases. However, a role for ARNO in VEGF-dependent endothelial processes has so far not been documented. Therefore, we investigated whether ARNO has a role in VEGF-dependent activation of endothelial cells and thus vessel permeability. METHODS AND RESULTS: ARNO expression was observed in endothelial cells in vitro by RT-PCR, western blotting, and immunofluorescence as well as ex vivo by immunohistochemical staining of mouse aorta. Treatment with the cytohesin inhibitor SecinH3 or with an ARNO siRNA prevented VEGF-dependent Akt activation, assessed by detection of phosphorylated Akt, and proliferation of endothelial cells in vitro, measured by methylthiazoletetrazolium (MTT) reduction. In addition, ARNO suppression reduced VEGF-induced permeability in vessels of the mouse (C57BL/6) cremaster muscle in vivo, as measured by extravasation of fluorescein isothiocyanate (FITC)-dextran. Moreover, ARNO knock-down accelerated ligand-induced reduction in vascular endothelial growth factor receptor-2 (VEGFR-2) surface expression, internalization, and degradation, as assessed by flow cytometry and western blotting, respectively. CONCLUSION: Our findings indicate an important and novel role for endothelial ARNO in VEGF-dependent initiation of angiogenesis by regulation of VEGFR-2 internalization in endothelial cells, resulting in the activation of the Akt pathway, vessel permeability, and ultimately endothelial proliferation. Thus, ARNO may be a new essential player in endothelial signalling and angiogenesis.
AIMS: The vascular endothelial growth factor (VEGF) stimulates angiogenesis by induction of vessel permeability, proliferation, and migration of endothelial cells, an important process in ischaemic diseases. ADP-ribosylation factor (ARF) nucleotide-binding site opener (ARNO) (cytohesin-2) is a guanine exchange factor important for cellular signalling through ARF GTPases. However, a role for ARNO in VEGF-dependent endothelial processes has so far not been documented. Therefore, we investigated whether ARNO has a role in VEGF-dependent activation of endothelial cells and thus vessel permeability. METHODS AND RESULTS:ARNO expression was observed in endothelial cells in vitro by RT-PCR, western blotting, and immunofluorescence as well as ex vivo by immunohistochemical staining of mouse aorta. Treatment with the cytohesin inhibitor SecinH3 or with an ARNO siRNA prevented VEGF-dependent Akt activation, assessed by detection of phosphorylated Akt, and proliferation of endothelial cells in vitro, measured by methylthiazoletetrazolium (MTT) reduction. In addition, ARNO suppression reduced VEGF-induced permeability in vessels of the mouse (C57BL/6) cremaster muscle in vivo, as measured by extravasation of fluorescein isothiocyanate (FITC)-dextran. Moreover, ARNO knock-down accelerated ligand-induced reduction in vascular endothelial growth factor receptor-2 (VEGFR-2) surface expression, internalization, and degradation, as assessed by flow cytometry and western blotting, respectively. CONCLUSION: Our findings indicate an important and novel role for endothelial ARNO in VEGF-dependent initiation of angiogenesis by regulation of VEGFR-2 internalization in endothelial cells, resulting in the activation of the Akt pathway, vessel permeability, and ultimately endothelial proliferation. Thus, ARNO may be a new essential player in endothelial signalling and angiogenesis.
Authors: Miruna Popa; Sibgha Tahir; Julia Elrod; Su Hwan Kim; Florian Leuschner; Thorsten Kessler; Peter Bugert; Ulrich Pohl; Andreas H Wagner; Markus Hecker Journal: Proc Natl Acad Sci U S A Date: 2018-05-23 Impact factor: 11.205
Authors: Julie Ouellette; Xavier Toussay; Cesar H Comin; Luciano da F Costa; Mirabelle Ho; María Lacalle-Aurioles; Moises Freitas-Andrade; Qing Yan Liu; Sonia Leclerc; Youlian Pan; Ziying Liu; Jean-François Thibodeau; Melissa Yin; Micael Carrier; Cameron J Morse; Peter Van Dyken; Christopher J Bergin; Sylvain Baillet; Christopher R Kennedy; Marie-Ève Tremblay; Yannick D Benoit; William L Stanford; Dylan Burger; Duncan J Stewart; Baptiste Lacoste Journal: Nat Neurosci Date: 2020-07-13 Impact factor: 24.884
Authors: Philipp Blüm; Joachim Pircher; Monika Merkle; Thomas Czermak; Andrea Ribeiro; Hanna Mannell; Florian Krötz; Alexander Hennrich; Michael Spannagl; Simone Köppel; Erik Gaitzsch; Markus Wörnle Journal: Cell Mol Immunol Date: 2016-04-18 Impact factor: 11.530
Authors: Yvonn Heun; Kristin Pogoda; Martina Anton; Joachim Pircher; Alexander Pfeifer; Markus Woernle; Andrea Ribeiro; Petra Kameritsch; Olga Mykhaylyk; Christian Plank; Florian Kroetz; Ulrich Pohl; Hanna Mannell Journal: Mol Ther Date: 2017-04-20 Impact factor: 11.454
Authors: Weiquan Zhu; Dallas S Shi; Jacob M Winter; Bianca E Rich; Zongzhong Tong; Lise K Sorensen; Helong Zhao; Yi Huang; Zhengfu Tai; Tara M Mleynek; Jae Hyuk Yoo; Christine Dunn; Jing Ling; Jake A Bergquist; Jackson R Richards; Amanda Jiang; Lisa A Lesniewski; M Elizabeth Hartnett; Diane M Ward; Alan L Mueller; Kirill Ostanin; Kirk R Thomas; Shannon J Odelberg; Dean Y Li Journal: J Clin Invest Date: 2017-10-23 Impact factor: 14.808
Authors: Joachim Pircher; Monika Merkle; Markus Wörnle; Andrea Ribeiro; Thomas Czermak; Yvonn Stampnik; Hanna Mannell; Markus Niemeyer; Volker Vielhauer; Florian Krötz Journal: Arthritis Res Ther Date: 2012-10-18 Impact factor: 5.156